Augmentin for Mastitis
Augmentin (amoxicillin-clavulanate) can be used for lactational mastitis, but it is NOT the optimal first-line antibiotic choice based on current resistance patterns and available evidence.
Key Recommendation
While Augmentin is safe during breastfeeding 1, recent data shows concerning resistance patterns that make it a suboptimal empirical choice. A 2025 international audit found amoxicillin/clavulanate was commonly prescribed in some countries (57-69% in Croatia and Turkey) 2, but a 2018 study demonstrated that amoxicillin-clavulanate showed significant resistance as first-line empirical therapy for breast abscesses, with MRSA being the predominant organism (50.8% of S. aureus isolates) 3.
Clinical Approach
When Augmentin May Be Appropriate:
- Culture-proven susceptibility to amoxicillin-clavulanate
- Mastitis caused by documented enterobacteria or anaerobes 4
- Mild cases of mastitis where MRSA is unlikely based on local antibiogram
Preferred Empirical Alternatives:
First-line empirical therapy should be:
- Flucloxacillin, cephalexin, or cefuroxime (used in 62-86% of cases in Australia, Brazil, and Germany) 2
- Ciprofloxacin plus clindamycin for MRSA coverage 3
Treatment Algorithm:
- Continue breastfeeding - mothers with mastitis are encouraged to continue nursing; regular milk removal is essential adjunctive therapy 5
- Obtain milk culture and sensitivity when possible (only available in 44% of cases in one audit) 2
- Start empirical antibiotics targeting S. aureus (most common pathogen, 33% of cultures) 2
- Switch to targeted therapy once culture results available
- Monitor for abscess formation (occurs in ~10% of mastitis cases) 5
Safety During Lactation
If Augmentin is used, it is safe for the breastfeeding infant 1, 6. However, dose-dependent adverse effects occur in infants:
- 22.3% of infants experienced minor adverse effects (primarily GI symptoms)
- Risk increases significantly with higher maternal doses (p=0.0139)
- All effects were self-limiting and did not require cessation of breastfeeding 6
Ampicillin-class antibiotics are excreted in breast milk, so caution is warranted 1.
Critical Pitfalls
⚠️ Major caveat: The evidence base for antibiotic choice in mastitis is weak. A Cochrane review found insufficient evidence to confirm or refute antibiotic effectiveness overall, with only small, low-quality trials available 7, 8.
⚠️ Do not delay treatment waiting for culture results in symptomatic women - most present after >48 hours of symptoms 2
⚠️ Local resistance patterns matter - institutional antibiograms should guide empirical choices 3
⚠️ Breastfeeding must continue on the affected breast unless purulent drainage contacts the infant's mouth 5
Bottom Line
Use flucloxacillin, cephalexin, or cefuroxime as first-line empirical therapy for lactational mastitis rather than Augmentin, given emerging MRSA resistance patterns 3, 2. Reserve Augmentin for culture-proven susceptible organisms or when other agents are contraindicated. The medication is safe during lactation but carries higher infant adverse effect rates than alternatives 6.